• Homepage
  • News Details (for English News)

Ypsomed gains a further customer in Russia

Ypsomed gains a further customer in Russia - ServoPen GEROPHARM
Ypsomed's platform strategy is the key to success in this new partnership with GEROPHARM.

Burgdorf, 20 December 2016, 7 a.m. – The human insulin of Russian pharmaceutical company GEROPHARM will in future be administered with a pen from Ypsomed's ServoPen® platform. This is a further confirmation of Ypsomed's platform strategy in the field of injection systems.

GEROPHARM will initially be marketing the reusable RinsaPen I, based on Ypsomed's ServoPen® platform, for the administration of its 3.0 ml cartridges of recombinant human insulins Rinsulin® R and Rinsulin® NPH as well as GEROPHARM’s insulin analogs to be launched in 2018 in the Russian Federation. The RinsaPen I was adapted by Ypsomed to meet the specific customer needs and will now be manufactured in Burgdorf. For CEO Simon Michel, Ypsomed's platform strategy is the key to success in this new partnership. “GEROPHARM appreciates our broad spectrum of injection systems which meet their high demands in terms of quality and reliable delivery. The flexible adaptation of the product to the specific needs and the quick availability for sales strengthened GEROPHARM 's decision in favour of Ypsomed.", is how the company's CEO summarises the latest success.

About GEROPHARM
GEROPHARM is a Russian pharmaceutical company which has been operating successfully in the pharmaceutical industry for 15 years and boasts a portfolio of over ten different medicinal products. The company is specialized in pharmaceuticals in the fields of neurology, ophthalmology, endocrinology and gynecology. Pipeline includes over 15 new products, of which seven are insulin analogs and modern oral anti-diabetic drugs. Own company’s R&D centre specializes in all aspects of drug and pharmaceutical development. GEROPHARM is the first Russian manufacturer of recombinant human insulin, which is produced on the full cycle basis: from scratch substance to the finished filled drug form.

For further information, please contact Benjamin Overney, Head of Investor & Public Relations at Ypsomed Holding AG, at the telephone number +41 34 424 41 59 or by email (benjamin.overney@ypsomed.com).

Related information

From platform to custom products - A systematic approach to customer projects

Torna indietro